Virtual Library
Start Your Search
R. Wood
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-012 - Impact of Brain Metastases on the Humanistic Burden Incurred by Patients with Advanced Non-small Cell Lung Cancer (A-nsclc) (ID 8179)
09:00 - 09:00 | Author(s): R. Wood
- Abstract
Background:
It is well documented that brain metastases negatively impact the prognosis for patients with A-NSCLC. However, it is less well known how secondary brain tumours impact health status, quality of life (QoL) and productivity in these patients. As such, an analysis of data from A-NSCLC patients was conducted to evaluate whether the metastatic site (brain vs non-brain) impacts the burden of disease.
Method:
Data were collected between May 2015 and June 2016 from adult patients with Stage IIIB or IV NSCLC via medical chart reviews and patient self-completion forms as part of a multicentre, cross-sectional study conducted in France, Germany and Italy. Health status was measured using the EQ-5D-3L (including the visual analogue scale, EQ-VAS), QoL using the EORTC QLQ-C30 and work/activity impairment using the WPAI:GH questionnaire. Outcomes were stratified by metastatic site (brain vs non-brain); no adjustments were made for possible confounding factors. Statistical significance was assessed using Mann–Whitney U tests.
Result:
1030 patients were recruited: mean patient age, 64.5 years; male, 65.9%; current/former smokers, 77.9%. Most patients had Stage IV NSCLC (88.4%), non-squamous histology (70.3%) and/or were receiving first-line therapy (70.5%). Patients were largely receiving chemotherapy, regardless of line of therapy. Of 910 evaluable Stage IV patients, 111 had brain metastases and 799 had non-brain metastases. Significant differences were observed between patients with brain metastases versus non-brain metastases for health status, QoL and activity-related impairments (TABLE). The percentage of work-related impairment was also numerically higher in patients with brain metastases. Figure 1
Conclusion:
Patients with A-NSCLC and secondary brain tumours had significantly worse health status and QoL, and experienced greater work- and activity-related impairments, compared with A-NSCLC patients with non-brain metastases. These findings may indicate a need for specific management/support programmes for patients with A-NSCLC and brain metastases.
